Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

53.95USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$53.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
111,133
52-wk High
$66.55
52-wk Low
$38.15

Latest Key Developments (Source: Significant Developments)

Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING.AERIE PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION.  Full Article

Aerie Pharmaceuticals Gets U.S. FDA Approval Of Glaucoma Drug
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - REMAIN ON TRACK TO FILE ROCLATAN NEW DRUG APPLICATION TO FDA IN Q2 2018.AERIE PHARMACEUTICALS - RHOPRESSA APPROVED AHEAD OF SCHEDULED PDUFA DATE OF FEBRUARY 28, 2018.  Full Article

Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - ‍for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018​.  Full Article

Aerie Pharmaceuticals Q3 loss per share $0.89
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - ‍as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments​.  Full Article

Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​.  Full Article

Aerie Pharmaceuticals enters into controlled equity offering sales agreement with Cantor Fitzgerald
Thursday, 25 May 2017 

May 25 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals - on May 25, co entered into controlled equity offering sales agreement with Cantor Fitzgerald & Co. - SEC filing.Aerie Pharmaceuticals - under agreement co may offer and sell shares of common stock, having an aggregate offering price of up to $50 million.  Full Article

Aerie Pharma's Roclatan succeeds in second late-stage study
Wednesday, 24 May 2017 

May 24 (Reuters) - Aerie Pharmaceuticals Inc :Aerie pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results.Aerie pharmaceuticals inc - ‍roclatan™ successfully achieves primary efficacy endpoint in mercury 2 study​.Aerie pharmaceuticals inc - ‍if mercury 1 12-month safety results are also successful, we expect to submit roclatan nda in first half of 2018​.  Full Article

Aerie pharmaceuticals updates full-year 2016 cash burn guidance
Thursday, 22 Sep 2016 

Aerie Pharmaceuticals Inc : Expects cash and cash equivalents to total approximately $230 million as of December 31, 2016 . Updated full-year 2016 cash burn guidance to approximately $85 million, an increase from previous guidance of $75 million .Updated guidance reflects initiatives like start-up of clinical trials in Japan, construction of manufacturing plant in Ireland.  Full Article

Aerie Pharmaceuticals submits NDA to U.S. Food and drug administration for Rhopressa
Tuesday, 6 Sep 2016 

Aerie Pharmaceuticals Inc :Submits new drug application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02 percent.  Full Article

Aerie pharmaceuticals reports Q2 2016 financial results and provides business update
Wednesday, 3 Aug 2016 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 GAAP loss per share $0.87 . Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S . Q2 adjusted loss per share $0.72 .Aerie Pharmaceuticals Inc says remains on track to file its NDA for Rhopressa(TM)(Netarsudil Ophthalmic Solution) 0.02% in Q3 of 2016.  Full Article

BRIEF-Aerie Pharmaceuticals Reports Q4 Adjusted Loss Per Share $1.38

* AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE